Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and Neurocognitive Training for Depression
NCT03237286Phase 2Completed
- Sponsor
- Rebecca Price
- Start
- Dec 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by Rebecca Price. Started Dec 2017; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03237286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237286.